ClinicalTrials.gov record
Not listed Phase 3 Interventional Accepts healthy volunteers

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

ClinicalTrials.gov ID: NCT04540185

Public ClinicalTrials.gov record NCT04540185. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 8:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19

Study identification

NCT ID
NCT04540185
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Biomed Industries, Inc.
Industry
Enrollment
3,600 participants

Conditions and interventions

Interventions

  • Biological: oral polio vaccine Biological
  • Combination of oral polio vaccine and NA-831 Combination Product
  • Comparable Placebo Biological
  • Comparable Placebo of Oral Polio Vaccine and Placebo of drug Combination Product
  • Comparable Placebo of drug Drug
  • NA-831 Drug

Biological · Combination Product · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2020
Primary completion
Oct 31, 2022
Completion
Dec 30, 2022
Last update posted
Sep 8, 2020

2020 – 2022

United States locations

U.S. sites
8
U.S. states
3
U.S. cities
7
Facility City State ZIP Site status
Coronavirus Research Institute- Testing Site Los Angeles California 90095
Coronavirus Research Institute Orange California 92868
Coronavirus Research Institute-Testing Site Palo Alto California 94304
Coronavirus Research Testing Site San Francisco California 94110
Coronavirus Research Institute-Testing Site Sunnyvale California 94086
Coronavirus Research Institute Sunnyvale California 94086
Coronavirus Research Institute-Testing Site Naperville Illinois 60540
Coronavirus Research Institute-Testing Site- The Bronx New York 10467

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04540185, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 8, 2020 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04540185 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →